StockNews.com Upgrades Agios Pharmaceuticals (NASDAQ:AGIO) to Hold

Agios Pharmaceuticals (NASDAQ:AGIO) was upgraded by equities research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other brokerages also recently weighed in on AGIO. Leerink Partners downgraded Agios Pharmaceuticals from an “outperform” rating to a “market perform” rating and cut their price target for the company from $60.00 to $56.00 in a report on Friday, September 27th. Leerink Partnrs downgraded Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. Raymond James reiterated an “outperform” rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $55.00 price target on shares of Agios Pharmaceuticals in a report on Friday, November 1st. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Agios Pharmaceuticals currently has an average rating of “Hold” and a consensus price target of $52.33.

Agios Pharmaceuticals Price Performance

Shares of NASDAQ AGIO opened at $59.06 on Friday. The company has a market cap of $3.37 billion, a PE ratio of 5.20, a price-to-earnings-growth ratio of 0.47 and a beta of 0.75. Agios Pharmaceuticals has a 12 month low of $20.40 and a 12 month high of $60.21. The company has a 50-day simple moving average of $45.15 and a 200-day simple moving average of $42.90.

Insider Transactions at Agios Pharmaceuticals

In other news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction on Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the completion of the sale, the chief financial officer now directly owns 20,158 shares in the company, valued at $988,346.74. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders own 4.93% of the company’s stock.

Institutional Trading of Agios Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Acadian Asset Management LLC acquired a new stake in Agios Pharmaceuticals in the 2nd quarter valued at $37,000. Quest Partners LLC acquired a new stake in Agios Pharmaceuticals in the 2nd quarter valued at $40,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in Agios Pharmaceuticals by 21.4% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after purchasing an additional 363 shares in the last quarter. CWM LLC increased its holdings in Agios Pharmaceuticals by 554.7% in the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 1,836 shares in the last quarter. Finally, North Star Asset Management Inc. acquired a new stake in Agios Pharmaceuticals in the 2nd quarter valued at $216,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.